Loading stock data…
$62.45+0.04 (+0.07%)
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CG Oncology, Inc. in the Healthcare sector is trading at $61.84 with a market capitalization of $6.3B. Wall Street consensus targets $91.08 (13 analysts), implying a +47.3% move over the next 12 months. The stock is currently 24% below its 52-week high of $80.97, remaining 4.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.16M↑ | $1.08M↓ | $2.32M↑ | $1.67M | $0 |
| Gross Profit | -$2.77M↓ | -$1.88M↓ | -$748,000↓ | $89,000 | $0 |
| Operating Income | -$86.40M↓ | -$66.39M↓ | -$48.70M↑ | -$51.13M↓ | -$48.74M |
| Net Income | -$79.06M↓ | -$60.20M↓ | -$41.31M↑ | -$43.81M↓ | -$41.43M |
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigationa...